← Eichor
Study identifier: NCT07357428 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

Condition: Amyotrophic Lateral Sclerosis · Neuromuscular Disease · Stroke  ·  Sponsor: Paradromics

PhaseNA
Planned participants2
Who can joinAll sexes, 22 Years to 75 Years
Healthy volunteersNo

About this study

The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with impaired communication as a result of severe loss of voluntary motor control; and (2) to provide control of computer devices for individuals with severe loss of voluntary motor control of the upper extremity.

This description comes directly from the study's public registry record.

Talk to the study team

Paradromics Clinical Team  ·  (512) 559 4120  ·  clinical-team@paradromics.com

Always discuss trial participation with your own doctor first.

Locations (3)

University of California, DavisSacramento, California, United StatesRecruiting
Massachusetts General HospitalBoston, Massachusetts, United StatesRecruiting
University of MichiganAnn Arbor, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07357428